



**Contact:**

Douglas Doerfler  
President and Chief Executive Officer  
MaxCyte, Inc.  
(301) 944-1700

**For Immediate Release**

**MaxCyte To Be Featured at the 2005 BIO InvestorForum**

**Gaithersburg, MD, October 11, 2005** – MaxCyte, Inc., a clinical stage therapeutic company and pioneer in clinical scale, non-viral cell loading systems, announces Douglas Doerfler, President and CEO, will be presenting at the 2005 BIO InvestorForum in San Francisco at the Palace Hotel, Pacific Heights Room, on Wednesday, October 19, 2005, at 2:00 PM.

Mr. Doerfler will provide a brief corporate overview and discuss the company's preclinical and clinical product candidates, partnering activities, and enabling technology for therapeutic development and biotherapeutic manufacturing.

**About MaxCyte**

MaxCyte Inc. is a clinical stage company developing cell-based therapeutics primarily in the areas of oncology and regenerative medicine. MaxCyte's pipeline includes one product in Phase I/II clinical trials for the treatment of Chronic Lymphocytic Leukemia (CLL) and several preclinical candidates to treat a variety of diseases with unmet needs. The company also offers its unparalleled, customizable flow based cell loading technology to partners who take advantage of its advanced capabilities for cell-based therapeutic development and biotherapeutic (viral vector) manufacturing through licensing relationships. Partners are currently working to develop therapeutics for pulmonary, cardiovascular and infectious disease, cancer and regenerative medicine.

For more information, visit <http://www.maxcyte.com>.

*This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.*

###